Can you put it on the scales, please? http://femjoy.in.net femjoy.com “These encouraging findings confirm prior signals ofclinical activity seen with ganetespib in breast cancer,” Iman El-Hariry, Synta’s vice president of clinical research, said inthe statement. “The favorable safety profile, clear single-agent clinical activity, and strong rationale for combinationtherapy suggest ganetespib may have broad potential utility inbreast cancer.”